UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Management and prognosis of cerebral palsy

Author
Marc C Patterson, MD, FRACP
Section Editor
Carolyn Bridgemohan, MD
Deputy Editor
Carrie Armsby, MD, MPH

INTRODUCTION

Cerebral palsy (CP) is a heterogeneous group of permanent, nonprogressive clinical syndromes that are characterized by motor and postural dysfunction. These conditions, which range in severity, are due to abnormalities of the developing brain resulting from a variety of causes. Although the disorder itself is not progressive, the appearance of neuropathologic lesions and their clinical expression may change over time as the brain matures.

The management and prognosis of CP are reviewed here. The epidemiology, etiology, prevention, classification, clinical features, evaluation, and diagnosis of CP are discussed separately:

(See "Epidemiology, etiology, and prevention of cerebral palsy".)

(See "Clinical features and classification of cerebral palsy".)

(See "Evaluation and diagnosis of cerebral palsy".)

                                     

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Tue Sep 06 00:00:00 GMT+00:00 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Bagnato SJ, Campbell TF. Comprehensive neurodevelopmental evaluation of children with brain insults. In: Static Encephalopathies of Infancy and Childhood, Miller G, Ranier JC (Eds), Raven, New York 1992. p.27.
  2. Zuromski ES. The management of mental retardation. In: Static Encephalopathies of Infancy and Childhood, Miller G, Ramer JC (Eds), Raven, New York 1992. p.119.
  3. Finnie's Handling the Young Child with Cerebral Palsy at Home, 4th ed, Bower E (Ed), Butterworth Heinemann Elsevier, London 2009.
  4. Huang IC, Holzbauer JJ, Lee EJ, et al. Vocational rehabilitation services and employment outcomes for adults with cerebral palsy in the United States. Dev Med Child Neurol 2013; 55:1000.
  5. Waninge A, Rook RA, Dijkhuizen A, et al. Feasibility, test-retest reliability, and interrater reliability of the Modified Ashworth Scale and Modified Tardieu Scale in persons with profound intellectual and multiple disabilities. Res Dev Disabil 2011; 32:613.
  6. Rosenbaum P, Eliasson AC, Hidecker MJ, Palisano RJ. Classification in childhood disability: focusing on function in the 21st century. J Child Neurol 2014; 29:1036.
  7. Barty E, Caynes K, Johnston LM. Development and reliability of the Functional Communication Classification System for children with cerebral palsy. Dev Med Child Neurol 2016; 58:1036.
  8. Hidecker MJ, Paneth N, Rosenbaum PL, et al. Developing and validating the Communication Function Classification System for individuals with cerebral palsy. Dev Med Child Neurol 2011; 53:704.
  9. Landau WM. Clinical neuromythology II. Parables of palsy pills and PT pedagogy: a spastic dialectic. Neurology 1988; 38:1496.
  10. Glenn MB, Whyte J. The Practical Management of Spasticity in Children and Adults, Lea & Fegiber, Philadelphia 1990.
  11. Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society, Delgado MR, Hirtz D, et al. Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2010; 74:336.
  12. Patrick JH, Roberts AP, Cole GF. Therapeutic choices in the locomotor management of the child with cerebral palsy--more luck than judgement? Arch Dis Child 2001; 85:275.
  13. Petersen MC, Palmer FB. Advances in prevention and treatment of cerebral palsy. Ment Retard Dev Disabil Res Rev 2001; 7:30.
  14. Koman LA, Mooney JF 3rd, Smith BP, et al. Management of spasticity in cerebral palsy with botulinum-A toxin: report of a preliminary, randomized, double-blind trial. J Pediatr Orthop 1994; 14:299.
  15. Dursun N, Dursun E, Alican D. The role of botulinum toxin a in the management of lower limb spasticity in patients with cerebral palsy. Int J Clin Pract 2002; 56:564.
  16. Baker R, Jasinski M, Maciag-Tymecka I, et al. Botulinum toxin treatment of spasticity in diplegic cerebral palsy: a randomized, double-blind, placebo-controlled, dose-ranging study. Dev Med Child Neurol 2002; 44:666.
  17. Polak F, Morton R, Ward C, et al. Double-blind comparison study of two doses of botulinum toxin A injected into calf muscles in children with hemiplegic cerebral palsy. Dev Med Child Neurol 2002; 44:551.
  18. Cardoso ES, Rodrigues BM, Barroso M, et al. Botulinum toxin type A for the treatment of the spastic equinus foot in cerebral palsy. Pediatr Neurol 2006; 34:106.
  19. Tedroff K, Löwing K, Haglund-Akerlind Y, et al. Botulinum toxin A treatment in toddlers with cerebral palsy. Acta Paediatr 2010; 99:1156.
  20. Hoare BJ, Wallen MA, Imms C, et al. Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy (UPDATE). Cochrane Database Syst Rev 2010; :CD003469.
  21. Novak I, McIntyre S, Morgan C, et al. A systematic review of interventions for children with cerebral palsy: state of the evidence. Dev Med Child Neurol 2013; 55:885.
  22. Delgado MR, Tilton A, Russman B, et al. AbobotulinumtoxinA for Equinus Foot Deformity in Cerebral Palsy: A Randomized Controlled Trial. Pediatrics 2016; 137:e20152830.
  23. Bleck EE. Cerebral palsy hip deformities: is there a consensus? II. Botulinum toxin A: a clinical experiment. J Pediatr Orthop 1994; 14:281.
  24. Neville B. Botulinum toxin in the cerebral palsies. BMJ 1994; 309:1526.
  25. Tedroff K, Granath F, Forssberg H, Haglund-Akerlind Y. Long-term effects of botulinum toxin A in children with cerebral palsy. Dev Med Child Neurol 2009; 51:120.
  26. Bjornson K, Hays R, Graubert C, et al. Botulinum toxin for spasticity in children with cerebral palsy: a comprehensive evaluation. Pediatrics 2007; 120:49.
  27. Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 1994; 9:213.
  28. Brin MF. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve Suppl 1997; 6:S146.
  29. Moore AP, Ade-Hall RA, Smith CT, et al. Two-year placebo-controlled trial of botulinum toxin A for leg spasticity in cerebral palsy. Neurology 2008; 71:122.
  30. Simpson DM, Gracies JM, Graham HK, et al. Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008; 70:1691.
  31. Koman LA, Mooney JF 3rd, Smith BP, et al. Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trial. BOTOX Study Group. J Pediatr Orthop 2000; 20:108.
  32. Koman LA, Brashear A, Rosenfeld S, et al. Botulinum toxin type a neuromuscular blockade in the treatment of equinus foot deformity in cerebral palsy: a multicenter, open-label clinical trial. Pediatrics 2001; 108:1062.
  33. Love SC, Novak I, Kentish M, et al. Botulinum toxin assessment, intervention and after-care for lower limb spasticity in children with cerebral palsy: international consensus statement. Eur J Neurol 2010; 17 Suppl 2:9.
  34. Van Campenhout A, Bar-On L, Desloovere K, et al. Motor endplate-targeted botulinum toxin injections of the gracilis muscle in children with cerebral palsy. Dev Med Child Neurol 2015; 57:476.
  35. Boyd RN, Hays RM. Current evidence for the use of botulinum toxin type A in the management of children with cerebral palsy: a systematic review. Eur J Neurol 2001; 8 Suppl 5:1.
  36. Copeland L, Edwards P, Thorley M, et al. Botulinum toxin A for nonambulatory children with cerebral palsy: a double blind randomized controlled trial. J Pediatr 2014; 165:140.
  37. Pascual-Pascual SI, Pascual-Castroviejo I. Safety of botulinum toxin type A in children younger than 2 years. Eur J Paediatr Neurol 2009; 13:511.
  38. Molenaers G, Van Campenhout A, Fagard K, et al. The use of botulinum toxin A in children with cerebral palsy, with a focus on the lower limb. J Child Orthop 2010; 4:183.
  39. Müller K, Mix E, Adib Saberi F, et al. Prevalence of neutralising antibodies in patients treated with botulinum toxin type A for spasticity. J Neural Transm (Vienna) 2009; 116:579.
  40. Dressler D. Clinical features of antibody-induced complete secondary failure of botulinum toxin therapy. Eur Neurol 2002; 48:26.
  41. Benecke R. Clinical relevance of botulinum toxin immunogenicity. BioDrugs 2012; 26:e1.
  42. Herrmann J, Geth K, Mall V, et al. Clinical impact of antibody formation to botulinum toxin A in children. Ann Neurol 2004; 55:732.
  43. Russman BS, Tilton A, Gormley ME Jr. Cerebral palsy: a rational approach to a treatment protocol, and the role of botulinum toxin in treatment. Muscle Nerve Suppl 1997; 6:S181.
  44. Heinen F, Desloovere K, Schroeder AS, et al. The updated European Consensus 2009 on the use of Botulinum toxin for children with cerebral palsy. Eur J Paediatr Neurol 2010; 14:45.
  45. 2008 Early communication about an ongoing safety review of Botox and Botox Cosmetic (Botulinum toxin Type A) and Myobloc (Botulinum toxin type B), February 2008. Available at: www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm070366.htm (Accessed on August 05, 2009).
  46. US Food and Drug Administration. Information for healthcare professionals: OnabotulinumtoxinA (marketed as Botox/Botox Cosmetic), AbobotulinumtoxinA (marketed as Dysport) and RimabotulinumtoxinB (marketed as Myobloc). www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm174949.htm (Accessed on August 05, 2009).
  47. O'Flaherty SJ, Janakan V, Morrow AM, et al. Adverse events and health status following botulinum toxin type A injections in children with cerebral palsy. Dev Med Child Neurol 2011; 53:125.
  48. Edwards P, Sakzewski L, Copeland L, et al. Safety of Botulinum Toxin Type A for Children With Nonambulatory Cerebral Palsy. Pediatrics 2015; 136:895.
  49. Montané E, Vallano A, Laporte JR. Oral antispastic drugs in nonprogressive neurologic diseases: a systematic review. Neurology 2004; 63:1357.
  50. Milla PJ, Jackson AD. A controlled trial of baclofen in children with cerebral palsy. J Int Med Res 1977; 5:398.
  51. Haslam RH, Walcher JR, Lietman PS, et al. Dantrolene sodium in children with spasticity. Arch Phys Med Rehabil 1974; 55:384.
  52. Joynt RL, Leonard JA Jr. Dantrolene sodium suspension in treatment of spastic cerebral palsy. Dev Med Child Neurol 1980; 22:755.
  53. Mathew A, Mathew MC, Thomas M, Antonisamy B. The efficacy of diazepam in enhancing motor function in children with spastic cerebral palsy. J Trop Pediatr 2005; 51:109.
  54. Davidoff RA. Antispasticity drugs: mechanisms of action. Ann Neurol 1985; 17:107.
  55. Young RR, Delwaide PJ. Drug therapy: spasticity (second of two parts). N Engl J Med 1981; 304:96.
  56. Utili R, Boitnott JK, Zimmerman HJ. Dantrolene-associated hepatic injury. Incidence and character. Gastroenterology 1977; 72:610.
  57. Scheinberg A, Hall K, Lam LT, O'Flaherty S. Oral baclofen in children with cerebral palsy: a double-blind cross-over pilot study. J Paediatr Child Health 2006; 42:715.
  58. Terrence CF, Fromm GH. Complications of baclofen withdrawal. Arch Neurol 1981; 38:588.
  59. Motta F, Buonaguro V, Stignani C. The use of intrathecal baclofen pump implants in children and adolescents: safety and complications in 200 consecutive cases. J Neurosurg 2007; 107:32.
  60. Pin TW, McCartney L, Lewis J, Waugh MC. Use of intrathecal baclofen therapy in ambulant children and adolescents with spasticity and dystonia of cerebral origin: a systematic review. Dev Med Child Neurol 2011; 53:885.
  61. Butler C, Campbell S. Evidence of the effects of intrathecal baclofen for spastic and dystonic cerebral palsy. AACPDM Treatment Outcomes Committee Review Panel. Dev Med Child Neurol 2000; 42:634.
  62. Brennan PM, Whittle IR. Intrathecal baclofen therapy for neurological disorders: a sound knowledge base but many challenges remain. Br J Neurosurg 2008; 22:508.
  63. Ramstad K, Jahnsen R, Lofterod B, Skjeldal OH. Continuous intrathecal baclofen therapy in children with cerebral palsy - when does improvement emerge? Acta Paediatr 2010; 99:1661.
  64. Morton RE, Gray N, Vloeberghs M. Controlled study of the effects of continuous intrathecal baclofen infusion in non-ambulant children with cerebral palsy. Dev Med Child Neurol 2011; 53:736.
  65. Albright AL. Baclofen in the treatment of cerebral palsy. J Child Neurol 1996; 11:77.
  66. Albright AL, Gilmartin R, Swift D, et al. Long-term intrathecal baclofen therapy for severe spasticity of cerebral origin. J Neurosurg 2003; 98:291.
  67. Ghosh D, Mainali G, Khera J, Luciano M. Complications of intrathecal baclofen pumps in children: experience from a tertiary care center. Pediatr Neurosurg 2013; 49:138.
  68. www.accessdata.fda.gov/drugsatfda_docs/label/2015/022462s008lbl.pdf (Accessed on February 23, 2015).
  69. Aquilina K, Graham D, Wimalasundera N. Selective dorsal rhizotomy: an old treatment re-emerging. Arch Dis Child 2015; 100:798.
  70. McLaughlin J, Bjornson K, Temkin N, et al. Selective dorsal rhizotomy: meta-analysis of three randomized controlled trials. Dev Med Child Neurol 2002; 44:17.
  71. Steinbok P, Reiner AM, Beauchamp R, et al. A randomized clinical trial to compare selective posterior rhizotomy plus physiotherapy with physiotherapy alone in children with spastic diplegic cerebral palsy. Dev Med Child Neurol 1997; 39:178.
  72. Wright FV, Sheil EM, Drake JM, et al. Evaluation of selective dorsal rhizotomy for the reduction of spasticity in cerebral palsy: a randomized controlled tria. Dev Med Child Neurol 1998; 40:239.
  73. McLaughlin JF, Bjornson KF, Astley SJ, et al. Selective dorsal rhizotomy: efficacy and safety in an investigator-masked randomized clinical trial. Dev Med Child Neurol 1998; 40:220.
  74. Mittal S, Farmer JP, Al-Atassi B, et al. Long-term functional outcome after selective posterior rhizotomy. J Neurosurg 2002; 97:315.
  75. Dudley RW, Parolin M, Gagnon B, et al. Long-term functional benefits of selective dorsal rhizotomy for spastic cerebral palsy. J Neurosurg Pediatr 2013; 12:142.
  76. Bolster EA, van Schie PE, Becher JG, et al. Long-term effect of selective dorsal rhizotomy on gross motor function in ambulant children with spastic bilateral cerebral palsy, compared with reference centiles. Dev Med Child Neurol 2013; 55:610.
  77. Josenby AL, Wagner P, Jarnlo GB, et al. Motor function after selective dorsal rhizotomy: a 10-year practice-based follow-up study. Dev Med Child Neurol 2012; 54:429.
  78. Tedroff K, Löwing K, Åström E. A prospective cohort study investigating gross motor function, pain, and health-related quality of life 17 years after selective dorsal rhizotomy in cerebral palsy. Dev Med Child Neurol 2015; 57:484.
  79. Cole GF, Farmer SE, Roberts A, et al. Selective dorsal rhizotomy for children with cerebral palsy: the Oswestry experience. Arch Dis Child 2007; 92:781.
  80. Koy A, Hellmich M, Pauls KA, et al. Effects of deep brain stimulation in dyskinetic cerebral palsy: a meta-analysis. Mov Disord 2013; 28:647.
  81. Vidailhet M, Yelnik J, Lagrange C, et al. Bilateral pallidal deep brain stimulation for the treatment of patients with dystonia-choreoathetosis cerebral palsy: a prospective pilot study. Lancet Neurol 2009; 8:709.
  82. Marks WA, Honeycutt J, Acosta F Jr, et al. Dystonia due to cerebral palsy responds to deep brain stimulation of the globus pallidus internus. Mov Disord 2011; 26:1748.
  83. Bieck EE. Orthopaedic Management in Cerebral Palsy, Mackeith, Oxford 1987.
  84. Koop SE. Orthopedic aspects of static encephalopathies. In: Static Encephalopathies of Infancy and Childhood, Miller G, Ramer JC (Eds), Raven, New York 1992. p.95.
  85. Cornell MS. The hip in cerebral palsy. Dev Med Child Neurol 1995; 37:3.
  86. Bleck EE. Management of the lower extremities in children who have cerebral palsy. J Bone Joint Surg Am 1990; 72:140.
  87. Sutherland DH, Davids JR. Common gait abnormalities of the knee in cerebral palsy. Clin Orthop Relat Res 1993; :139.
  88. Baddar A, Granata K, Damiano DL, et al. Ankle and knee coupling in patients with spastic diplegia: effects of gastrocnemius-soleus lengthening. J Bone Joint Surg Am 2002; 84-A:736.
  89. Autti-Rämö I, Suoranta J, Anttila H, et al. Effectiveness of upper and lower limb casting and orthoses in children with cerebral palsy: an overview of review articles. Am J Phys Med Rehabil 2006; 85:89.
  90. Blackmore AM, Boettcher-Hunt E, Jordan M, Chan MD. A systematic review of the effects of casting on equinus in children with cerebral palsy: an evidence report of the AACPDM. Dev Med Child Neurol 2007; 49:781.
  91. Lannin NA, Novak I, Cusick A. A systematic review of upper extremity casting for children and adults with central nervous system motor disorders. Clin Rehabil 2007; 21:963.
  92. Abel MF, Damiano DL, Pannunzio M, Bush J. Muscle-tendon surgery in diplegic cerebral palsy: functional and mechanical changes. J Pediatr Orthop 1999; 19:366.
  93. Van Heest AE, Bagley A, Molitor F, James MA. Tendon transfer surgery in upper-extremity cerebral palsy is more effective than botulinum toxin injections or regular, ongoing therapy. J Bone Joint Surg Am 2015; 97:529.
  94. Flynn JM, Miller F. Management of hip disorders in patients with cerebral palsy. J Am Acad Orthop Surg 2002; 10:198.
  95. Gordon GS, Simkiss DE. A systematic review of the evidence for hip surveillance in children with cerebral palsy. J Bone Joint Surg Br 2006; 88:1492.
  96. Dobson F, Boyd RN, Parrott J, et al. Hip surveillance in children with cerebral palsy. Impact on the surgical management of spastic hip disease. J Bone Joint Surg Br 2002; 84:720.
  97. Hägglund G, Andersson S, Düppe H, et al. Prevention of dislocation of the hip in children with cerebral palsy. The first ten years of a population-based prevention programme. J Bone Joint Surg Br 2005; 87:95.
  98. Scrutton D, Baird G, Smeeton N. Hip dysplasia in bilateral cerebral palsy: incidence and natural history in children aged 18 months to 5 years. Dev Med Child Neurol 2001; 43:586.
  99. Graham HK, Boyd R, Carlin JB, et al. Does botulinum toxin a combined with bracing prevent hip displacement in children with cerebral palsy and "hips at risk"? A randomized, controlled trial. J Bone Joint Surg Am 2008; 90:23.
  100. Morgan C, Darrah J, Gordon AM, et al. Effectiveness of motor interventions in infants with cerebral palsy: a systematic review. Dev Med Child Neurol 2016; 58:900.
  101. Sakzewski L, Ziviani J, Abbott DF, et al. Randomized trial of constraint-induced movement therapy and bimanual training on activity outcomes for children with congenital hemiplegia. Dev Med Child Neurol 2011; 53:313.
  102. Sakzewski L, Ziviani J, Boyd RN. Efficacy of upper limb therapies for unilateral cerebral palsy: a meta-analysis. Pediatrics 2014; 133:e175.
  103. Huang HH, Fetters L, Hale J, McBride A. Bound for success: a systematic review of constraint-induced movement therapy in children with cerebral palsy supports improved arm and hand use. Phys Ther 2009; 89:1126.
  104. Charles JR, Wolf SL, Schneider JA, Gordon AM. Efficacy of a child-friendly form of constraint-induced movement therapy in hemiplegic cerebral palsy: a randomized control trial. Dev Med Child Neurol 2006; 48:635.
  105. Deluca SC, Echols K, Law CR, Ramey SL. Intensive pediatric constraint-induced therapy for children with cerebral palsy: randomized, controlled, crossover trial. J Child Neurol 2006; 21:931.
  106. Hoare BJ, Wasiak J, Imms C, Carey L. Constraint-induced movement therapy in the treatment of the upper limb in children with hemiplegic cerebral palsy. Cochrane Database Syst Rev 2007; :CD004149.
  107. Tinderholt Myrhaug H, Østensjø S, Larun L, et al. Intensive training of motor function and functional skills among young children with cerebral palsy: a systematic review and meta-analysis. BMC Pediatr 2014; 14:292.
  108. Law MC, Darrah J, Pollock N, et al. Focus on function: a cluster, randomized controlled trial comparing child- versus context-focused intervention for young children with cerebral palsy. Dev Med Child Neurol 2011; 53:621.
  109. Novak I, Cusick A, Lannin N. Occupational therapy home programs for cerebral palsy: double-blind, randomized, controlled trial. Pediatrics 2009; 124:e606.
  110. Ketelaar M, Vermeer A, Hart H, et al. Effects of a functional therapy program on motor abilities of children with cerebral palsy. Phys Ther 2001; 81:1534.
  111. Lannin N, Scheinberg A, Clark K. AACPDM systematic review of the effectiveness of therapy for children with cerebral palsy after botulinum toxin A injections. Dev Med Child Neurol 2006; 48:533.
  112. Fehlings D, Novak I, Berweck S, et al. Botulinum toxin assessment, intervention and follow-up for paediatric upper limb hypertonicity: international consensus statement. Eur J Neurol 2010; 17 Suppl 2:38.
  113. Butler JM, Scianni A, Ada L. Effect of cardiorespiratory training on aerobic fitness and carryover to activity in children with cerebral palsy: a systematic review. Int J Rehabil Res 2010; 33:97.
  114. Verschuren O, Ketelaar M, Takken T, et al. Exercise programs for children with cerebral palsy: a systematic review of the literature. Am J Phys Med Rehabil 2008; 87:404.
  115. Rogers A, Furler BL, Brinks S, Darrah J. A systematic review of the effectiveness of aerobic exercise interventions for children with cerebral palsy: an AACPDM evidence report. Dev Med Child Neurol 2008; 50:808.
  116. Butler C, Darrah J. Effects of neurodevelopmental treatment (NDT) for cerebral palsy: an AACPDM evidence report. Dev Med Child Neurol 2001; 43:778.
  117. Martin L, Baker R, Harvey A. A systematic review of common physiotherapy interventions in school-aged children with cerebral palsy. Phys Occup Ther Pediatr 2010; 30:294.
  118. Bar-Haim S, Harries N, Nammourah I, et al. Effectiveness of motor learning coaching in children with cerebral palsy: a randomized controlled trial. Clin Rehabil 2010; 24:1009.
  119. Vargas S, Camilli G. A meta-analysis of research on sensory integration treatment. Am J Occup Ther 1999; 53:189.
  120. Blauw-Hospers CH, Hadders-Algra M. A systematic review of the effects of early intervention on motor development. Dev Med Child Neurol 2005; 47:421.
  121. Ziviani J, Feeney R, Rodger S, Watter P. Systematic review of early intervention programmes for children from birth to nine years who have a physical disability. Aust Occup Ther J 2010; 57:210.
  122. Winkle M, Crowe TK, Hendrix I. Service dogs and people with physical disabilities partnerships: a systematic review. Occup Ther Int 2012; 19:54.
  123. Jones MA, McEwen IR, Neas BR. Effects of power wheelchairs on the development and function of young children with severe motor impairments. Pediatr Phys Ther 2012; 24:131.
  124. Whalen CN, Case-Smith J. Therapeutic effects of horseback riding therapy on gross motor function in children with cerebral palsy: a systematic review. Phys Occup Ther Pediatr 2012; 32:229.
  125. Dodd KJ, Taylor NF, Damiano DL. A systematic review of the effectiveness of strength-training programs for people with cerebral palsy. Arch Phys Med Rehabil 2002; 83:1157.
  126. Mockford M, Caulton JM. Systematic review of progressive strength training in children and adolescents with cerebral palsy who are ambulatory. Pediatr Phys Ther 2008; 20:318.
  127. Zwicker JG, Mayson TA. Effectiveness of treadmill training in children with motor impairments: an overview of systematic reviews. Pediatr Phys Ther 2010; 22:361.
  128. Mutlu A, Krosschell K, Spira DG. Treadmill training with partial body-weight support in children with cerebral palsy: a systematic review. Dev Med Child Neurol 2009; 51:268.
  129. Darrah J, Watkins B, Chen L, et al. Conductive education intervention for children with cerebral palsy: an AACPDM evidence report. Dev Med Child Neurol 2004; 46:187.
  130. Kerr C, McDowell B, Cosgrove A, et al. Electrical stimulation in cerebral palsy: a randomized controlled trial. Dev Med Child Neurol 2006; 48:870.
  131. van der Linden ML, Hazlewood ME, Aitchison AM, et al. Electrical stimulation of gluteus maximus in children with cerebral palsy: effects on gait characteristics and muscle strength. Dev Med Child Neurol 2003; 45:385.
  132. Dali Cí, Hansen FJ, Pedersen SA, et al. Threshold electrical stimulation (TES) in ambulant children with CP: a randomized double-blind placebo-controlled clinical trial. Dev Med Child Neurol 2002; 44:364.
  133. Kerr C, McDowell B, McDonough S. Electrical stimulation in cerebral palsy: a review of effects on strength and motor function. Dev Med Child Neurol 2004; 46:205.
  134. Cauraugh JH, Naik SK, Hsu WH, et al. Children with cerebral palsy: a systematic review and meta-analysis on gait and electrical stimulation. Clin Rehabil 2010; 24:963.
  135. McDonagh MS, Morgan D, Carson S, Russman BS. Systematic review of hyperbaric oxygen therapy for cerebral palsy: the state of the evidence. Dev Med Child Neurol 2007; 49:942.
  136. Collet JP, Vanasse M, Marois P, et al. Hyperbaric oxygen for children with cerebral palsy: a randomised multicentre trial. HBO-CP Research Group. Lancet 2001; 357:582.
  137. Lacey DJ, Stolfi A, Pilati LE. Effects of hyperbaric oxygen on motor function in children with cerebral palsy. Ann Neurol 2012; 72:695.
  138. Dahl M, Thommessen M, Rasmussen M, Selberg T. Feeding and nutritional characteristics in children with moderate or severe cerebral palsy. Acta Paediatr 1996; 85:697.
  139. Reilly S, Skuse D, Poblete X. Prevalence of feeding problems and oral motor dysfunction in children with cerebral palsy: a community survey. J Pediatr 1996; 129:877.
  140. Andrew MJ, Parr JR, Sullivan PB. Feeding difficulties in children with cerebral palsy. Arch Dis Child Educ Pract Ed 2012; 97:222.
  141. Sullivan PB, Lambert B, Rose M, et al. Prevalence and severity of feeding and nutritional problems in children with neurological impairment: Oxford Feeding Study. Dev Med Child Neurol 2000; 42:674.
  142. Fung EB, Samson-Fang L, Stallings VA, et al. Feeding dysfunction is associated with poor growth and health status in children with cerebral palsy. J Am Diet Assoc 2002; 102:361.
  143. Samson-Fang LJ, Stevenson RD. Identification of malnutrition in children with cerebral palsy: poor performance of weight-for-height centiles. Dev Med Child Neurol 2000; 42:162.
  144. Stevenson RD. Use of segmental measures to estimate stature in children with cerebral palsy. Arch Pediatr Adolesc Med 1995; 149:658.
  145. Sullivan PB, Juszczak E, Bachlet AM, et al. Gastrostomy tube feeding in children with cerebral palsy: a prospective, longitudinal study. Dev Med Child Neurol 2005; 47:77.
  146. Brant CQ, Stanich P, Ferrari AP Jr. Improvement of children's nutritional status after enteral feeding by PEG: an interim report. Gastrointest Endosc 1999; 50:183.
  147. Kong CK, Wong HS. Weight-for-height values and limb anthropometric composition of tube-fed children with quadriplegic cerebral palsy. Pediatrics 2005; 116:e839.
  148. Ferluga ED, Archer KR, Sathe NA, et al. Interventions for Feeding and Nutrition in Cerebral Palsy. Comp Effectiveness Review, US Department of Health and Human Services; Agency for Healthcare Research and Quality, Rockville, MD 2013.
  149. Smith SW, Camfield C, Camfield P. Living with cerebral palsy and tube feeding: A population-based follow-up study. J Pediatr 1999; 135:307.
  150. Gisel E. Gastrostomy feeding in cerebral palsy: too much of a good thing? Dev Med Child Neurol 2006; 48:869.
  151. Brooks J, Day S, Shavelle R, Strauss D. Low weight, morbidity, and mortality in children with cerebral palsy: new clinical growth charts. Pediatrics 2011; 128:e299.
  152. Lespargot A, Langevin MF, Muller S, Guillemont S. Swallowing disturbances associated with drooling in cerebral-palsied children. Dev Med Child Neurol 1993; 35:298.
  153. Little SA, Kubba H, Hussain SS. An evidence-based approach to the child who drools saliva. Clin Otolaryngol 2009; 34:236.
  154. Crysdale WS, McCann C, Roske L, et al. Saliva control issues in the neurologically challenged. A 30 year experience in team management. Int J Pediatr Otorhinolaryngol 2006; 70:519.
  155. Reddihough D, Johnson H, Staples M, et al. Use of benzhexol hydrochloride to control drooling of children with cerebral palsy. Dev Med Child Neurol 1990; 32:985.
  156. Siegel LK, Klingbeil MA. Control of drooling with transdermal scopolamine in a child with cerebral palsy. Dev Med Child Neurol 1991; 33:1013.
  157. Mato A, Limeres J, Tomás I, et al. Management of drooling in disabled patients with scopolamine patches. Br J Clin Pharmacol 2010; 69:684.
  158. Jongerius PH, van den Hoogen FJ, van Limbeek J, et al. Effect of botulinum toxin in the treatment of drooling: a controlled clinical trial. Pediatrics 2004; 114:620.
  159. Jongerius PH, Rotteveel JJ, van Limbeek J, et al. Botulinum toxin effect on salivary flow rate in children with cerebral palsy. Neurology 2004; 63:1371.
  160. Scheffer AR, Erasmus C, van Hulst K, et al. Efficacy and duration of botulinum toxin treatment for drooling in 131 children. Arch Otolaryngol Head Neck Surg 2010; 136:873.
  161. Webb K, Reddihough DS, Johnson H, et al. Long-term outcome of saliva-control surgery. Dev Med Child Neurol 1995; 37:755.
  162. Sellars SL. Surgery of sialorrhoea. J Laryngol Otol 1985; 99:1107.
  163. Greensmith AL, Johnstone BR, Reid SM, et al. Prospective analysis of the outcome of surgical management of drooling in the pediatric population: a 10-year experience. Plast Reconstr Surg 2005; 116:1233.
  164. Glynn F, O'Dwyer TP. Does the addition of sublingual gland excision to submandibular duct relocation give better overall results in drooling control? Clin Otolaryngol 2007; 32:103.
  165. Scheffer AR, Erasmus C, VAN Hulst K, et al. Botulinum toxin versus submandibular duct relocation for severe drooling. Dev Med Child Neurol 2010; 52:1038.
  166. Koheil R, Sochaniwskyj AE, Bablich K, et al. Biofeedback techniques and behaviour modification in the conservative remediation of drooling by children with cerebral palsy. Dev Med Child Neurol 1987; 29:19.
  167. Arvedson J, Clark H, Lazarus C, et al. The effects of oral-motor exercises on swallowing in children: an evidence-based systematic review. Dev Med Child Neurol 2010; 52:1000.
  168. Henderson RC, Lark RK, Kecskemethy HH, et al. Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial. J Pediatr 2002; 141:644.
  169. Plotkin H, Coughlin S, Kreikemeier R, et al. Low doses of pamidronate to treat osteopenia in children with severe cerebral palsy: a pilot study. Dev Med Child Neurol 2006; 48:709.
  170. Fehlings D, Switzer L, Agarwal P, et al. Informing evidence-based clinical practice guidelines for children with cerebral palsy at risk of osteoporosis: a systematic review. Dev Med Child Neurol 2012; 54:106.
  171. Ozel S, Switzer L, Macintosh A, Fehlings D. Informing evidence-based clinical practice guidelines for children with cerebral palsy at risk of osteoporosis: an update. Dev Med Child Neurol 2016; 58:918.
  172. Cohen M, Lahat E, Bistritzer T, et al. Evidence-based review of bone strength in children and youth with cerebral palsy. J Child Neurol 2009; 24:959.
  173. Caulton JM, Ward KA, Alsop CW, et al. A randomised controlled trial of standing programme on bone mineral density in non-ambulant children with cerebral palsy. Arch Dis Child 2004; 89:131.
  174. Jekovec-Vrhovsek M, Kocijancic A, Prezelj J. Effect of vitamin D and calcium on bone mineral density in children with CP and epilepsy in full-time care. Dev Med Child Neurol 2000; 42:403.
  175. Hough JP, Boyd RN, Keating JL. Systematic review of interventions for low bone mineral density in children with cerebral palsy. Pediatrics 2010; 125:e670.
  176. Whittaker S, Tomlinson R. Question 2: Do standing frames and other related physical therapies reduce the risk of fractures in children with cerebral palsy? Arch Dis Child 2015; 100:1181.
  177. Murphy KP, Boutin SA, Ide KR. Cerebral palsy, neurogenic bladder, and outcomes of lifetime care. Dev Med Child Neurol 2012; 54:945.
  178. Olshanksy S. Chronic sorrow: a response to having a mentally defective child. Soc Casework 1962; 43:190.
  179. Taylor DC. Counselling the parents of handicapped children. Br Med J (Clin Res Ed) 1982; 284:1027.
  180. Barowsky El. Communicating information. In: Static Encephalopathies of Infancy and Childhood, Miller G, Ranier JC (Eds), Raven, New York 1992. p.111.
  181. Bentovim A. Emotional disturbances of handicapped pre-school children and their families--attitudes to the child. Br Med J 1972; 3:579.
  182. Murphy NA, Carbone PS, American Academy of Pediatrics Council on Children With Disabilities. Promoting the participation of children with disabilities in sports, recreation, and physical activities. Pediatrics 2008; 121:1057.
  183. McBurney H, Taylor NF, Dodd KJ, Graham HK. A qualitative analysis of the benefits of strength training for young people with cerebral palsy. Dev Med Child Neurol 2003; 45:658.
  184. Light J, McNaughton D. Supporting the communication, language, and literacy development of children with complex communication needs: state of the science and future research priorities. Assist Technol 2011; 24:34.
  185. Almeida MA, Piza MH, Lamônica DA. [Adaptation of the picture exchange communication system in a school context]. Pro Fono 2005; 17:233.
  186. Crichton JU, Mackinnon M, White CP. The life-expectancy of persons with cerebral palsy. Dev Med Child Neurol 1995; 37:567.
  187. Hutton JL, Cooke T, Pharoah PO. Life expectancy in children with cerebral palsy. BMJ 1994; 309:431.
  188. Hemming K, Hutton JL, Colver A, Platt MJ. Regional variation in survival of people with cerebral palsy in the United Kingdom. Pediatrics 2005; 116:1383.
  189. Westbom L, Bergstrand L, Wagner P, Nordmark E. Survival at 19 years of age in a total population of children and young people with cerebral palsy. Dev Med Child Neurol 2011; 53:808.
  190. Brooks JC, Strauss DJ, Shavelle RM, et al. Recent trends in cerebral palsy survival. Part II: individual survival prognosis. Dev Med Child Neurol 2014; 56:1065.
  191. Eyman RK, Grossman HJ, Chaney RH, Call TL. Survival of profoundly disabled people with severe mental retardation. Am J Dis Child 1993; 147:329.
  192. Crothers B, Paine S. The Natural History of Cerebral Palsy, Harvard University Press, Cambridge 1959.
  193. Molnar GE, Gordon SU. Cerebral palsy: predictive value of selected clinical signs for early prognostication of motor function. Arch Phys Med Rehabil 1976; 57:153.
  194. Bleck EE. Locomotor prognosis in cerebral palsy. Dev Med Child Neurol 1975; 17:18.
  195. da Paz Júnior AC, Burnett SM, Braga LW. Walking prognosis in cerebral palsy: a 22-year retrospective analysis. Dev Med Child Neurol 1994; 36:130.
  196. Sala DA, Grant AD. Prognosis for ambulation in cerebral palsy. Dev Med Child Neurol 1995; 37:1020.
  197. Rosenbaum PL, Walter SD, Hanna SE, et al. Prognosis for gross motor function in cerebral palsy: creation of motor development curves. JAMA 2002; 288:1357.
  198. Kinsman SL. Predicting gross motor function in cerebral palsy. JAMA 2002; 288:1399.
  199. Arnaud C, White-Koning M, Michelsen SI, et al. Parent-reported quality of life of children with cerebral palsy in Europe. Pediatrics 2008; 121:54.
  200. Dickinson HO, Parkinson KN, Ravens-Sieberer U, et al. Self-reported quality of life of 8-12-year-old children with cerebral palsy: a cross-sectional European study. Lancet 2007; 369:2171.
  201. Colver A, Rapp M, Eisemann N, et al. Self-reported quality of life of adolescents with cerebral palsy: a cross-sectional and longitudinal analysis. Lancet 2015; 385:705.